4RXD
T. Brucei Farnesyl Diphosphate Synthase Complexed with Risedronate
Summary for 4RXD
| Entry DOI | 10.2210/pdb4rxd/pdb |
| Related | 4RXC |
| Descriptor | Farnesyl pyrophosphate synthase, MAGNESIUM ION, 1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE BIS-PHOSPHONIC ACID, ... (4 entities in total) |
| Functional Keywords | transferase |
| Biological source | Trypanosoma brucei |
| Total number of polymer chains | 3 |
| Total formula weight | 134495.29 |
| Authors | Cao, R.,Liu, Y.-L.,Oldfield, E. (deposition date: 2014-12-10, release date: 2015-04-15, Last modification date: 2023-09-20) |
| Primary citation | Liu, Y.L.,Cao, R.,Wang, Y.,Oldfield, E. Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries. ACS Med Chem Lett, 6:349-354, 2015 Cited by PubMed Abstract: Farnesyl diphosphate synthase (FPPS) is an important drug target for bone resorption, cancer, and some infectious diseases. Here, we report five new structures including two having unique bound ligand geometries. The diamidine inhibitor 7 binds to human FPPS close to the homoallylic (S2) and allosteric (S3) sites and extends into a new site, here called S4. With the bisphosphonate inhibitor 8, two molecules bind to Trypanosoma brucei FPPS, one molecule in the allylic site (S1) and the other close to S2, the first observation of two bisphosphonate molecules bound to FPPS. We also report the structures of apo-FPPS from T. brucei, together with two more bisphosphonate-bound structures (2,9), for purposes of comparison. The diamidine structure is of particular interest because 7 could represent a new lead for lipophilic FPPS inhibitors, while 8 has low micromolar activity against T. brucei, the causative agent of human African trypanosomiasis. PubMed: 25815158DOI: 10.1021/ml500528x PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2 Å) |
Structure validation
Download full validation report
